Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back its sales.

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on Wednesday, ending a four-year stretch of steady guidance increases since the launch of its Wegovy weight-loss drug,